Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Project. For a description of this project, see the consortium grant made to the lead institution: University of California, Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Project. For a description of this project, see the consortium grant made to the lead institution: University of California, Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Project. For a description of this project, see the consortium grant made to the lead institution: University of California, Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Project. For a description of this project, see the consortium grant made to the lead institution: University of California, Santa Cruz, Santa Cruz, CA.

Analyzing the genetic code of each patient's cancer enables researchers to identify specific errors that fuel the cancer in that patient. While the genetic code of patients in the clinics analyzed, it is currently difficult to analyze each patient in the context of all other patients. The Treehouse Consortium enables real-time sharing of pediatric cancer data generated by studies and clinical trials across the world, uniting data from diverse sources into a compendium of unprecedented scale. This group developed and made available to others methods to compare each child's cancer against over 12,000 childhood and adult tumors to improve treatment decisions. Fund administered by University of California, Santa Cruz.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Project. For a description of this project, see the consortium grant made to the lead institution: University of California, Santa Cruz, Santa Cruz, CA.

Burkitt lymphoma (BL) is the fastest growing, most aggressive pediatric tumor. In the 1960s, it was universally fatal. Over the past decades, clinical trials identified very high dose chemotherapy therapies as effective. Over 95% of children with BL in the US now survive. However, over 80% of cases of BL arise in children in sub-Saharan Africa (SSA) and other lower income regions where high dose chemotherapy is not currently feasible and in these settings BL is typically fatal. In the study, Dr. Allen builds on the observation that BL tumors from US and SSA are largely indistinguishable, but surprisingly tonsils from children in SSA and US have vastly different gene expression patterns. He therefore hypothesizes that the much higher rate of BL in SSA may not be due to intrinsic cancer cell factors, rather due to the nature of lymphoid tissues out of which the cancer cells grow. If Dr. Allen and colleagues can identify factors that lead to BL, they hope to create opportunities to prevent and treat BL in SSA. This grant is funded by Danilo Gallinari and the National Basketball Players Association.

This proposal introduces four groundbreaking advancements in the treatment of Ewing sarcoma (EwS), a rare and aggressive cancer. Firstly, Dr. Li and colleagues aim to optimize and assess the effectiveness of cutting-edge anti-IL1RAP ADCs in treating EwS. Secondly, they seek to uncover new insights into the diversity and heterogeneity of targets within EwS tumors. Thirdly, will explore the potential of innovative bispecific ADCs to target a wider range of EwS cells, enhancing treatment efficacy and reducing the risk of relapse and spread. Lastly, Dr. Li will explore the possibility of applying these advancements to other IL1RAP+CD276+ cancers like acute myeloid leukemia (AML). Overall, this research holds promise for improving outcomes and broadening treatment options for patients with these challenging cancers. This grant is funded by and named for the D-Feet Cancer - The Dalton Fox Foundation. D-Feet Cancer - The Dalton Fox Foundation was established to honor and remember Dalton’s contagious smile and sense of humor, even on his toughest days with Ewing Sarcoma. He is an inspiration and the reason for the mission and interest in finding targeted therapies and treatments for Ewing Sarcoma, a pediatric bone cancer.

Adoptive immunotherapy has demonstrated unprecedented success in the treatment of pediatric leukemia. Extending its therapeutic potential to other pediatric malignancies such as glioblastoma (GBM) has proved challenging. In this therapy, T cells are isolated from a patient, expanded outside of the body, and genetically modified prior to reinfusion. The ability of these T cells to recognize and eliminate cancer cells is improved by expressing a protein (CAR) on the T cell surface. An important challenge is to minimize the manipulation of patients' T cells outside the body. Prolonged culture compromises their efficacy. Dr. Ghassemi developed approaches to generate CAR T cells in 1 day. These cells have increased potency. She is combining this recent development with a metabolic strategy to overcome the metabolic nature of tumor environment. This synthetic advancement combined with the production of CAR T cells in 1 day will lead to superior CAR T cells for cellular immunotherapies against pediatric GBM. This grant is funded by and named for the Be Brooks Brave Fund. Despite his diagnosis at age 5 with inoperable brain and spinal tumors, Brooks taught so many people what life is truly about--love. He was BRAVE beyond his years with an inspiring “faith over fear” attitude. This Hero Fund hopes to raise money for high-grade glioma research so no other family will hear the words, “there is no cure”.

The majority of children with newly diagnosed Burkitt lymphoma (BL) are cured. Unfortunately, the outcome is poor for patients whose disease returns (relapse). The relapse is caused by multiple reasons but mainly is due to drug resistance and suppression by the tumor surroundings. Novel therapeutic approaches are urgently needed. Natural killer (NK) cells can attack cancer cells. Dr. Cairo is developing immunotherapeutic agents to enhance the functions of NK cells to kill BL. Expanded NK cells will be modified by genetic techniques to specifically target CD20 and a special protein will be developed to bind to another surface protein CD19 on BL. A virus will be created to secrete IL21 to enhance NK persistence and function. If successful, the combinatorial therapies will become available to pediatric BL patients in the clinical setting and would offer a potentially more effective and less toxic therapeutic approach, ultimately leading to improved survival. This grant is funded by and named for Jack's Pack - We Still Have His Back, a St. Baldrick's Hero Fund. Jack Klein was a ten year old who loved life, laughing and monkeys. During his illness, his community of family and friends near and far rallied around him under the moniker "Jack's Pack". Their slogan was "We have Jack's Back". After Jack succumbed to Burkitt's Lymphoma, his "pack" focused their energy and efforts to funding a cure...just as Jack would have wanted.

There has been little recent progress in treating Ewing sarcoma, a pediatric tumor involving bone. Dr. Stegmaier and colleagues have used a technology called CRISPR to identify urgently needed, new therapeutic targets for this disease. They prioritized a class of targets which are expressed in immature but not mature tissues. These proteins are often abnormally re-expressed in cancers such as Ewing sarcoma. Thus, drugs targeting these proteins would be expected to have minimal toxicity. The Stegmaier lab identified the target IGF2BP1 as a top selective gene dependency in Ewing sarcoma; deletion of IGF2BP1 was more deleterious to Ewing sarcoma than all other cancer types screened. Importantly, IGF2BP1 is not expressed in most normal human cells. Dr. Stegmaier will validate IGF2BP1 as a therapeutic target in Ewing and will determine the mechanisms by which Ewing sarcoma cells rely on IGF2BP1 for growth. With IGF2BP1 chemical inhibitors in development, this project has exciting translational potential for patients with Ewing sarcoma. This grant is funded by and named for The Ben Brandenburg Fund for Ewing Sarcoma Research. Ben passed away at the age of 15. He is remembered for his quick wit, indomitable spirit and bravery. This fund is his lasting legacy and ensures that research is funded so fewer children will have to suffer from Ewing Sarcoma.